Companies

Keros Therapeutics, Inc.

KROS · CIK 0001664710 · operating

$13.91-1.97%Last updated Mar 3, 1:26 AM

Key Statistics

Valuation

Market Cap$423.78M
P/E8.92
Fwd P/E-3.58
PEG
P/S1.72
P/B0.80
EV/EBITDA-5.26
EV/Rev-1.02

Profitability

Gross Margin
Op. Margin-5938.96%
Net Margin-5277.55%
ROE-32.78%
ROA-30.42%
FCF Margin-4585.92%

Financial Health

Current Ratio21.45
Debt/Equity0.08
Free Cash Flow-$162.80M
Div. Yield

Growth & Other

Revenue Growth2250.99%
EPS Growth3.85%
Beta0.90
52W High$22.55
52W Low$9.12

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc. (KROS) is a pharmaceutical preparations company, listed on the Nasdaq. With a market capitalization of $424 million, Keros Therapeutics, Inc. is a small-cap company. The stock currently trades at $13.91, down 1.97% today, with a 52-week range of $9.12–$22.55. The company trades at a trailing P/E of 9.1x.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2024$-5.00$-5.00+3.8%
2023$-5.20$-5.20-25.3%
2022$-4.15$-4.15-64.7%
2021$-2.52$-2.52
2020

Annual Reports (10-K) · 5 filings

Report DateFiledAccession Number
2024-12-312025-02-260001664710-25-000018SEC ↗
2023-12-312024-02-280001664710-24-000017SEC ↗
2022-12-312023-03-030001664710-23-000021SEC ↗
2021-12-312022-03-090001664710-22-000011SEC ↗
2020-12-312021-03-250001664710-21-000018SEC ↗